[PRESS RELEASE] – TALLAHASSEE, Fla., June 9, 2026 – Trulieve Cannabis Corp., a leading and top-performing medical cannabis company in the U.S., announced that its board of directors authorized a share repurchase program pursuant to which the company may repurchase up to the lesser of (i) $50 million in aggregate value, and (ii) 8,495,038 subordinate voting shares of the company (being 5% of the company's issued and outstanding subordinate voting shares as at June 8, 2026) over 12 months.
"This program reflects our confidence in the long-term value of the business and our disciplined approach to capital allocation," Trulieve founder and CEO Kim Rivers said. "We view share repurchases as an important tool to deliver value to shareholders when market conditions present a compelling opportunity, while maintaining the flexibility to invest in growth and strengthen our balance sheet."
Repurchases under the program will be executed in accordance with applicable securities laws and regulations. While the company intends to proceed with the repurchase program, the repurchase program does not obligate the company to acquire any specific number of subordinated voting shares and may be suspended, modified or discontinued at any time at the company's discretion.
The repurchase program will expire on June 16, 2027, and any subordinate voting shares purchased pursuant to the repurchase program will be canceled.
